3 Stocks Underperforming Today In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 16,384 as of Monday, March 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 999 issues advancing vs. 1,928 declining with 160 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Incyte ( INCY), down 2.5%, Novo Nordisk A/S ( NVO), down 1.4%, Vertex Pharmaceuticals ( VRTX), down 1.4%, Valeant Pharmaceuticals International ( VRX), down 1.0% and Shire ( SHPG), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Illumina ( ILMN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Illumina is down $2.99 (-1.8%) to $165.36 on average volume. Thus far, 1.4 million shares of Illumina exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $163.09-$168.54 after having opened the day at $167.68 as compared to the previous trading day's close of $168.35.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.0 billion and is part of the health care sector. Shares are up 55.0% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Actavis ( ACT) is down $4.07 (-1.9%) to $209.11 on heavy volume. Thus far, 1.8 million shares of Actavis exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $206.49-$212.74 after having opened the day at $209.56 as compared to the previous trading day's close of $213.18.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $37.3 billion and is part of the health care sector. Shares are up 27.4% year-to-date as of the close of trading on Friday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.41 (-0.5%) to $79.17 on light volume. Thus far, 4.3 million shares of Gilead exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $78.35-$79.93 after having opened the day at $79.40 as compared to the previous trading day's close of $79.58.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $122.9 billion and is part of the health care sector. Shares are up 6.4% year-to-date as of the close of trading on Friday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec